Information  X 
Enter a valid email address

Synairgen FY pretax loss £2.5m

By BFN News | 07:39 AM | Wednesday 13 February, 2013

Synairgen said in a trading update that its pretax loss for the six months to end-December 2012 was £2.5 million, from £2.2 million in the year-earlier same period. "In 2012 our interferon beta programme achieved a significant milestone, generating persuasive efficacy data within the group of asthma patients that we are seeking to treat. We are now planning the further development of this exciting therapy and are focussed on securing the right partnership to help us deliver it," said chairman Simon Shaw. Story provided by

a d v e r t i s e m e n t